Paper Details

  1. Home
  2. Paper Details

Vemurafenib-induced granulomatous hepatitis.

Author: FontanaRobert J, KleinerDavid E, SpenglerErin K

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Vemurafenib is a protein kinase inhibitor used to treat patients with BRAF V600E mutated metastatic melanoma. While effective, it can cause side effects like arthralgia, rash, fatigue, and liver abnormalities. This case report details a patient who developed severe vemurafenib-induced granulomatous hepatitis leading to chronic cholestasis, highlighting the potential hepatotoxicity of this drug and other protein kinase inhibitors.
Paper Details　
Original Abstract of the Article :
Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated pat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/27335285

データ提供：米国国立医学図書館（NLM）

Vemurafenib-Induced Granulomatous Hepatitis: A Rare Side Effect

This case report delves into the potentially serious side effect of [vemurafenib], a promising treatment for [metastatic melanoma]. Think of this like a rare desert bloom, unexpected and sometimes challenging. This research examines the case of a patient who experienced [vemurafenib-induced granulomatous hepatitis], leading to [chronic cholestasis]. The authors also provide a comprehensive review of the [hepatotoxicity] associated with other [protein kinase inhibitors (PKIs)].

Navigating the Desert of Drug Side Effects: A Cautionary Tale

This case report serves as a reminder that even effective medications can have unexpected side effects. This study highlights the importance of closely monitoring patients for potential liver complications when they are being treated with [vemurafenib] and other [PKIs].

Understanding the Risks: A Desert Oasis of Knowledge

This study emphasizes the need for further research into the potential liver toxicity of [PKIs]. By understanding the risks associated with these medications, healthcare professionals can better protect their patients and navigate the complex landscape of drug side effects.

Dr.Camel's Conclusion

While vemurafenib can be an effective treatment for metastatic melanoma, it's crucial to be aware of the potential for serious side effects such as granulomatous hepatitis. This case report highlights the importance of close patient monitoring and continued research into the hepatotoxicity of protein kinase inhibitors.

Date :
  1. Date Completed 2017-08-07
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27335285

DOI: Digital Object Identifier

NIHMS797566

Related Literature

Article Analysis
・Side Effects of vemurafenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.